← All trials
NCT04440670
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 20, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Jun 22, 2020
- Last posted
- Nov 4, 2020
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangdong Women and Children HospitalLead sponsor
- Guangdong Women and Children HospitalReponsible party - principal investigator
- Guangdong Women and Children HospitalStudy chair
- Sun Yat-Sen UniversityCollaborator
- Guangdong Women and Children HospitalCollaborator
- Guangdong Cord Blood BankCollaborator
- Foshan Chancheng Central HospitalCollaborator
- Foshan Women and Children HospitalCollaborator
- Guangdong Women and Children HospitalCollaborator
- Southern Medical UniversityCollaborator
- Heyuan Women and Children HospitalCollaborator
- Guangzhou Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.